Cargando…

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis

INTRODUCTION: Global clinical trials in rheumatoid arthritis (RA) often do not recruit enough patients from diverse racial and ethnic backgrounds to identify any potential differences in treatment outcome across such groups. To overcome this limitation, using data from five previous clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Combe, Bernard, Besuyen, Robin, Gómez-Centeno, Antonio, Matsubara, Tsukasa, Sancho Jimenez, Juan José, Yin, Zhaoyu, Buch, Maya H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931958/ https://www.ncbi.nlm.nih.gov/pubmed/36205910 http://dx.doi.org/10.1007/s40744-022-00494-1

Ejemplares similares

Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
por: Aletaha, Daniel, et al.
Publicado: (2021)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
por: Balsa, Alejandro, et al.
Publicado: (2023)

Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
por: Winthrop, Kevin L, et al.
Publicado: (2022)

Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Correction to: Filgotinib in Rheumatoid Arthritis: A Profile of Its Use
por: Kim, Esther S., et al.
Publicado: (2021)

Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives
por: Tanaka, Yoshiya, et al.
Publicado: (2023)

Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
por: Tanaka, Yoshiya, et al.
Publicado: (2023)

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)
por: Orbai, Ana-Maria, et al.
Publicado: (2020)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice
por: Benucci, Maurizio, et al.
Publicado: (2023)

The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies
por: Bingham, Clifton O., et al.
Publicado: (2022)

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
por: Combe, Bernard, et al.
Publicado: (2021)

Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial
por: Maksymowych, Walter P, et al.
Publicado: (2021)

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
por: Combe, Bernard G., et al.
Publicado: (2022)

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
por: Combe, Bernard G., et al.
Publicado: (2023)

Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)
por: Maksymowych, Walter P, et al.
Publicado: (2021)

Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies
por: Meng, Amy, et al.
Publicado: (2022)

Filgotinib: First Approval
por: Dhillon, Sohita, et al.
Publicado: (2020)

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Grimm, Sabine E., et al.
Publicado: (2021)

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
por: Hibi, Toshifumi, et al.
Publicado: (2023)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
por: Genovese, Mark, et al.
Publicado: (2018)

Correction to: Filgotinib: First Approval
por: Dhillon, Sohita, et al.
Publicado: (2021)

Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
por: Tanaka, Yoshiya, et al.
Publicado: (2023)

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
por: Vanhoutte, Frédéric, et al.
Publicado: (2017)

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
por: Westhovens, René, et al.
Publicado: (2021)

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Filgotinib: A Clinical Pharmacology Review
por: Namour, Florence, et al.
Publicado: (2022)

Understanding emerging treatment paradigms in rheumatoid arthritis
por: Breedveld, Ferdinand C, et al.
Publicado: (2011)

'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps
por: Tan, Yvonne, et al.
Publicado: (2022)

Cytomegalovirus infection: friend or foe in rheumatoid arthritis?
por: Davignon, Jean-Luc, et al.
Publicado: (2021)

Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
por: Tanaka, Yoshiya, et al.
Publicado: (2022)

Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial
por: Shimizu, Toshimasa, et al.
Publicado: (2023)

Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations
por: Horton, Sarah, et al.
Publicado: (2010)

Glucocorticoids in rheumatoid arthritis: current status and future studies
por: Hua, Charlotte, et al.
Publicado: (2020)

Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials
por: Tarrant, Jacqueline M., et al.
Publicado: (2020)

Single-centre experience of refractory rheumatoid arthritis
por: Fitton, John, et al.
Publicado: (2022)

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
por: Ogata, Atsushi, et al.
Publicado: (2014)

Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort
por: Mouterde, Gaël, et al.
Publicado: (2019)

Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial
por: Chandran, Vinod, et al.
Publicado: (2023)

Lymphotoxin α revisited: general features and implications in rheumatoid arthritis
por: Calmon-Hamaty, Flavia, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_o0gaq7l7e43a719v46fda0g8p5